ImmunityBio, Inc. (IBRX)

4,9100 -0,3300 (-6,30%) Al cierre: 04:00PM EDT

ImmunityBio, Inc.

3530 John Hopkins Court
San Diego, CA 92121
United States
844 696 5235
https://immunitybio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 628

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.	Executive Chairman of the Board, Global Chief Scientific & Medical Officer	629,19k	N/A	1953
Mr. Richard Gerald Adcock	President, CEO & Director	849,45k	N/A	1969
Mr. David C. Sachs	CFO, Principal Financial Officer & Principal Accounting Officer	533,33k	N/A	1978
Dr. Barry J. Simon M.D.	Chief Corporate Affairs Officer & Director	N/A	N/A	1965
Dr. Leonard S. Sender M.D.	Chief Operating Officer	N/A	N/A	N/A
Dr. Enrique Diloné Ph.D., RAC	Chief Technology Officer	N/A	N/A	1967
Mr. Jason R. Liljestrom	General Counsel & Corporate Secretary	N/A	N/A	1983
Ms. Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy	N/A	N/A	N/A
Dr. Sandeep K. Reddy M.D.	Chief Medical Officer	N/A	N/A	N/A
Dr. Hans Georg Klingemann M.D., Ph.D.	Chief Science Officer of Cellular	N/A	N/A	1950

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de ImmunityBio, Inc., a día 1 de abril de 2024, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 9; Derechos de los accionistas: 6; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.